Targeting multidrug resistance in cancer
The DOI matches its Crossref record; 267 of the 267 references it cites were found in a registry or an index.
Abstract
Effective treatment of metastatic cancers usually requires the use of toxic chemotherapy. In most cases, multiple drugs are used, as resistance to single agents occurs almost universally. For this reason, elucidation of mechanisms that confer simultaneous resistance to different drugs with different targets and chemical structures - multidrug resistance - has been a major goal of cancer biologists during the past 35 years. Here, we review the most common of these mechanisms, one that relies on drug efflux from cancer cells mediated by ATP-binding cassette (ABC) transporters. We describe various approaches to combating multidrug-resistant cancer, including the development of drugs that engage, evade or exploit efflux by ABC transporters.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ROS also play an important role in multidrug resistance.”
From Reactive Oxygen Species in Cancer: Current Findings and Future Directions (2021) · cites this paper as [56]
Citations
Cites
1 retracted
Chang, G., & Roth, C. B. (2001) · Science · doi:10.1126/science.293.5536.1793 · Cited by 619
RetractedLipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536 · cited 1×
“Significance of ABC transporters in cancer Much has been learned about ABC transporters since MDR was first describe”
BackgroundSelf-citationABC Transporters: From Microorganisms to Man
Higgins, C. F. (1992) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.08.110192.000435 · Cited by 3,985 · cited 1×
“The ABC transporter family ABC transporters, named after their distinctive ATP-binding cassette domains, are conserved proteins that typically translocate solutes across cellular membrane”
BackgroundTumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668 · cited 1×
“According to the cancer stem cell model, this population of drug-resistant pluripotent cells defies treatment and serves as an unrestricted reservoir for drug-resistant tumour relaps”
BackgroundA surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
Monks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., Vaigro-Wolff, A., et al. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.11.757 · Cited by 3,289
Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037
Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I., & Willingham, M. C. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7735 · Cited by 2,777
Self-citationA multidrug resistance transporter from human MCF-7 breast cancer cells
Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., & Ross, D. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15665 · Cited by 2,322
Research works printed but not linked: 2
- van der Holt, B. et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 106, 2646–2654 (2005). · DOI · Paper page
- Joly, F. J. C. et al. A phase 3 study of PSC 833 in combination with paclitaxel and carboplatin (PC-PSC) versus paclitaxel and carboplatin (PC) alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary cancer of the peritoneum. Proc. Am. Soc. Clin. Oncol. 21, Abstract 806 (2002).
Cited by
Items 201–300 of 1,013
Novel strategies to prevent the development of multidrug resistance (MDR) in cancer
Wang, J., Seebacher, N., Shi, H., Kan, Q., & Duan, Z. (2017) · Oncotarget · doi:10.18632/oncotarget.19187 · Cited by 207
“Multidrug resistance (MDR) is a phenomenon by which, after exposure to a chemotherapeutic agent, cancer cells develop resistance, and simultaneous cross-resistance, to a wide range of functionally and structurally unrelated chemotherapeutic drugs [1, 2].”
BackgroundRecent advances in delivery of drug–nucleic acid combinations for cancer treatment
Li, J., Wang, Y., Zhu, Y., & Oupický, D. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.04.010 · Cited by 207
“It is important to control the silencing of Pgp expression specifically only in the tumor cells to avoid side effects caused by undesirable pharmacological activity in healthy organs and tissues [61].”
Molecular and cellular paradigms of multidrug resistance in cancer
Vaidya, F. U., Sufiyan Chhipa, A., Mishra, V., Gupta, V. K., Rawat, S. G., Kumar, A., & Pathak, C. (2022) · Cancer Reports · doi:10.1002/cnr2.1291 · Cited by 197
“P-gp holds the central position in multidrug resistant cells by diminishing the intracellular accumulation of chemotherapeutic agents.(26,27) The P-gp plays a vital role in the intestinal transport and efflux, which alters the bioavailability and pharmaceutical effects of orally administered pharmaceutical”
BackgroundRationally designed nanovehicles to overcome cancer chemoresistance
Livney, Y. D., & Assaraf, Y. G. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.006 · Cited by 205
Szakács, G., Hall, M. D., Gottesman, M. M., Boumendjel, A., Kachadourian, R., Day, B. J., Baubichon-Cortay, H., & Di Pietro, A. (2014) · Chemical Reviews · doi:10.1021/cr4006236 · Cited by 203
Self-citationDu, J.-Z., Mao, C.-Q., Yuan, Y.-Y., Yang, X.-Z., & Wang, J. (2014) · Biotechnology Advances · doi:10.1016/j.biotechadv.2013.08.002 · Cited by 202
Wang, L., Sun, Q., Wang, X., Wen, T., Yin, J.-J., Wang, P., Bai, R., Zhang, X.-Q., Zhang, L.-H., Lu, A.-H., et al. (2015) · Journal of the American Chemical Society · doi:10.1021/ja511560b · Cited by 204
TAT-modified nanosilver for combating multidrug-resistant cancer
Liu, J., Zhao, Y., Guo, Q., Wang, Z., Wang, H., Yang, Y., & Huang, Y. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.05.035 · Cited by 205
Mitochondrial ATP fuels ABC transporter-mediated drug efflux in cancer chemoresistance
Giddings, E. L., Champagne, D. P., Wu, M.-H., Laffin, J. M., Thornton, T. M., Valenca-Pereira, F., Culp-Hill, R., Fortner, K. A., Romero, N., East, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23071-6 · Cited by 199
Lespine, A., Ménez, C., Bourguinat, C., & Prichard, R. K. (2012) · International Journal for Parasitology: Drugs and Drug Resistance · doi:10.1016/j.ijpddr.2011.10.001 · Cited by 202
“In general, clinical trials of MDR reversing agents against multidrug resistant cancers have been unsuccessful (Nobili et al., 2006; Szakacs et al., 2006).”
BackgroundMagnetic Iron Oxide Nanoparticles for Biomedical Applications
Laurent, S., Bridot, J.-L., Vander Elst, L., & Muller, R. N. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.09.164 · Cited by 193
Heffeter, P., Pape, V. F. S., Enyedy, É. A., Keppler, B. K., Szakacs, G., & Kowol, C. R. (2019) · Antioxidants & Redox Signaling · doi:10.1089/ars.2017.7487 · Cited by 202
“This family of ATP-driven, membrane-spanning proteins is involved in the transmembrane transport of a vast array of potentially toxic molecules that include toxins, peptides, sugars, lipids, but also chemotherapeutics and diverse pharmaceutical agents (34, 49, 57, 177).”
Self-citationAptamer-Based SERRS Sensor for Thrombin Detection
Cho, H., Baker, B. R., Wachsmann-Hogiu, S., Pagba, C. V., Laurence, T. A., Lane, S. M., Lee, L. P., & Tok, J. B.-H. (2008) · Nano Letters · doi:10.1021/nl802245w · Cited by 200
A Tailored DNA Nanoplatform for Synergistic RNAi‐/Chemotherapy of Multidrug‐Resistant Tumors
Liu, J., Song, L., Liu, S., Zhao, S., Jiang, Q., & Ding, B. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201809452 · Cited by 203
Zhu, W., Xu, H., Zhu, D., Zhi, H., Wang, T., Wang, J., Jiang, B., Shu, Y., & Liu, P. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1752-3 · Cited by 199
“Unfortunately, drug resistance of cancer cells either intrinsic or acquired continues to be a dominating obstacle to the successful clinical cancer therapy [1].”
BackgroundABCG2 transports anticancer drugs via a closed-to-open switch
Orlando, B. J., & Liao, M. (2020) · Nature Communications · doi:10.1038/s41467-020-16155-2 · Cited by 198
Nanocarrier-mediated co-delivery of chemotherapeutic drugs and gene agents for cancer treatment
Kang, L., Gao, Z., Huang, W., Jin, M., & Wang, Q. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.03.001 · Cited by 195
Targeted Delivery of Doxorubicin to Mitochondria
Chamberlain, G. R., Tulumello, D. V., & Kelley, S. O. (2013) · ACS Chemical Biology · doi:10.1021/cb400095v · Cited by 198
Polymeric nanovehicles for anticancer drugs with triggering release mechanisms
Oh, K. T., Yin, H., Lee, E. S., & Bae, Y. H. (2007) · Journal of Materials Chemistry · doi:10.1039/b707142f · Cited by 196
Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells
Li, G., Guo, J., Shen, B.-Q., Yadav, D. B., Sliwkowski, M. X., Crocker, L. M., Lacap, J. A., & Phillips, G. D. L. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0296 · Cited by 193
“To verify expression, qRT-PCRwas performed for transporters with reported functions in cancer drug resistance (41).”
MethodProtective effects of curcumin against doxorubicin-induced toxicity and resistance: A review
Mohajeri, M., & Sahebkar, A. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.12.005 · Cited by 195
Malek, E., Jagannathan, S., & Driscoll, J. J. (2014) · Oncotarget · doi:10.18632/oncotarget.2469 · Cited by 195
“However, drug resistance inevitably emerges in most cancer types to hinder patient response [11–21].”
BackgroundRegulation of multidrug resistance by microRNAs in anti-cancer therapy
An, X., Sarmiento, C., Tan, T., & Zhu, H. (2017) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.09.002 · Cited by 194
Easmon, J., Pürstinger, G., Thies, K.-S., Heinisch, G., & Hofmann, J. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060232u · Cited by 190
Casi, G., & Neri, D. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00457 · Cited by 189
Phytochemicals and Biogenic Metallic Nanoparticles as Anticancer Agents
Rao, P. V., Nallappan, D., Madhavi, K., Rahman, S., Jun Wei, L., & Gan, S. H. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/3685671 · Cited by 192
“Nevertheless, these therapeutic approaches are linked to severe side effects, especially multidrug resistance (MDR) [5, 6].”
BackgroundXiao, Q., Zhao, W., Wu, C., Wang, X., Chen, J., Shi, X., Sha, S., Li, J., Liang, X., Yang, Y., et al. (2022) · Advanced Science · doi:10.1002/advs.202105274 · Cited by 188
Cancer chemotherapy resistance: Mechanisms and recent breakthrough in targeted drug delivery
Davodabadi, F., Sajjadi, S. F., Sarhadi, M., Mirghasemi, S., Nadali Hezaveh, M., Khosravi, S., Kamali Andani, M., Cordani, M., Basiri, M., & Ghavami, S. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176013 · Cited by 184
Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology
Xue, X., & Liang, X.-J. (2012) · Chinese Journal of Cancer · doi:10.5732/cjc.011.10326 · Cited by 187
Paumi, C. M., Chuk, M., Snider, J., Stagljar, I., & Michaelis, S. (2009) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00020-09 · Cited by 190
Cai, Q., Wang, S., Jin, L., Weng, M., Zhou, D., Wang, J., Tang, Z., & Quan, Z. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1016-0 · Cited by 190
miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2
Zhu, W., Zhu, D., Lu, S., Wang, T., Wang, J., Jiang, B., Shu, Y., & Liu, P. (2012) · Medical Oncology · doi:10.1007/s12032-010-9797-4 · Cited by 189
“to kill cells, including alterations in cell cycle, enhanced DNA repair activity, defective apoptosis pathway, altered metabolism of drugs, etc [2–5].”
BackgroundDetection and isolation of circulating tumor cells: Principles and methods
Esmaeilsabzali, H., Beischlag, T. V., Cox, M. E., Parameswaran, A. M., & Park, E. J. (2013) · Biotechnology Advances · doi:10.1016/j.biotechadv.2013.08.016 · Cited by 189
Small molecule-drug conjugates: A novel strategy for cancer-targeted treatment
Zhuang, C., Guan, X., Ma, H., Cong, H., Zhang, W., & Miao, Z. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.12.035 · Cited by 184
Maleki, A., Shahbazi, M., Alinezhad, V., & Santos, H. A. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202000248 · Cited by 188
Antibody–Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence
Gogia, P., Ashraf, H., Bhasin, S., & Xu, Y. (2023) · Cancers · doi:10.3390/cancers15153886 · Cited by 181
Zhang, W., Shen, J., Su, H., Mu, G., Sun, J.-H., Tan, C.-P., Liang, X.-J., Ji, L.-N., & Mao, Z.-W. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b03881 · Cited by 187
Gao, M., & Tang, B. Z. (2020) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2019.213076 · Cited by 187
Efflux Transporters: Newly Appreciated Roles in Protection against Pollutants
Epel, D., Luckenbach, T., Stevenson, C. N., MacManus-Spencer, L. A., Hamdoun, A., & Smital, A. T. (2008) · Environmental Science & Technology · doi:10.1021/es087187v · Cited by 184
“One consequence of chemosensitization is enhancement of toxicity (19); the inhibition of transporter activity decreases efficacy such that previously excluded toxicants can now enter the cell.”
BackgroundOld drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics
Wijdeven, R. H., Pang, B., Assaraf, Y. G., & Neefjes, J. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.07.001 · Cited by 187
The combination of disulfiram and copper for cancer treatment
Li, H., Wang, J., Wu, C., Wang, L., Chen, Z.-S., & Cui, W. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.04.003 · Cited by 185
Drug interactions at the blood-brain barrier: Fact or fantasy?☆
Eyal, S., Hsiao, P., & Unadkat, J. D. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.03.017 · Cited by 186
“…blocker verapamil can restore drug sensitivity in tumor cell lines (Tsuruo,1981), many agents have been investigated for their ability to inhibit P-gp and therefore reverse the multidrug resistance of tumors (for review, see Breedveld et al. (2006), Szakács et al. (2006) and Shukla et al. (2008)).”
Antibody-Drug Conjugates: The New Frontier of Chemotherapy
Ponziani, S., Di Vittorio, G., Pitari, G., Cimini, A. M., Ardini, M., Gentile, R., Iacobelli, S., Sala, G., Capone, E., Flavell, D. J., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155510 · Cited by 183
“The increased polarity introduced by such linkers allows the formation of maytansinoid metabolites that are poor substrates for efflux pumps thus overcoming MDR [55].”
BackgroundFan, J., To, K. K. W., Chen, Z.-S., & Fu, L. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100905 · Cited by 180
Nobili, S., Landini, I., Mazzei, T., & Mini, E. (2012) · Medicinal Research Reviews · doi:10.1002/med.20239 · Cited by 182
“MDR cell lines have been found to be collaterally sensitive to a relevant number of drugs structurally or functionally related or not to P-gp substrate anticancer drugs.(41,291) Since the first studies on modulation of tumor MDR due to P-gp, collateral sensitivity of MDR cells to substrates/inhibitors of P-gp, such as…”
BackgroundTian, G., Zheng, X., Zhang, X., Yin, W., Yu, J., Wang, D., Zhang, Z., Yang, X., Gu, Z., & Zhao, Y. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2014.11.022 · Cited by 182
“To overcomeMDR, considerable attempts have been made to develop P-gp inhibitors during the past decades [8,9].”
BackgroundKim, D., Gao, Z. G., Lee, E. S., & Bae, Y. H. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900021q · Cited by 183
Liu, T., Zeng, L., Jiang, W., Fu, Y., Zheng, W., & Chen, T. (2015) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.01.009 · Cited by 179
Waltzing transporters and 'the dance macabre' between humans and bacteria
Lomovskaya, O., Zgurskaya, H. I., Totrov, M., & Watkins, W. J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2200 · Cited by 183
Pluronic F-68 and F-127 Based Nanomedicines for Advancing Combination Cancer Therapy
Khaliq, N. U., Lee, J., Kim, S., Sung, D., & Kim, H. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082102 · Cited by 175
Boron Dipyrromethene Nano‐Photosensitizers for Anticancer Phototherapies
Sun, W., Zhao, X., Fan, J., Du, J., & Peng, X. (2019) · Small · doi:10.1002/smll.201804927 · Cited by 177
Structural basis for gating mechanisms of a eukaryotic P-glycoprotein homolog
Kodan, A., Yamaguchi, T., Nakatsu, T., Sakiyama, K., Hipolito, C. J., Fujioka, A., Hirokane, R., Ikeguchi, K., Watanabe, B., Hiratake, J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1321562111 · Cited by 178
Advances in antibody–drug conjugates: A new era of targeted cancer therapy
Sau, S., Alsaab, H. O., Kashaw, S. K., Tatiparti, K., & Iyer, A. K. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.05.011 · Cited by 174
“By contrast, pristine chemodrugs, such as vinblastine, doxorubicin, and paclitaxel, have limited use for cancer treatment because of their nonspecific toxicity, thus narrowing the therapeutic window and increasing drug resistance [4,5].”
BackgroundSu, H., Lai, H., Lin, Y., Liu, C., Chen, C., Chou, Y., Lin, S., Lin, W., Lee, H., & Yu, M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25083 · Cited by 176
Shen, W., Liu, W., Yang, H., Zhang, P., Xiao, C., & Chen, X. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.02.011 · Cited by 176
“However, the therapy outcome is usual ly significantly limited by the drug-resistance [1-3].”
BackgroundSildenafil Reverses ABCB1- and ABCG2-Mediated Chemotherapeutic Drug Resistance
Shi, Z., Tiwari, A. K., Shukla, S., Robey, R. W., Singh, S., Kim, I.-W., Bates, S. E., Peng, X., Abraham, I., Ambudkar, S. V., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3820 · Cited by 170
“These proteins share the ability to transport a large number of structurally diverse, mainly hydrophobic compounds from cells, but each transporter has their own specific substrates (2).”
BackgroundPaclitaxel Nanocrystals for Overcoming Multidrug Resistance in Cancer
Liu, Y., Huang, L., & Liu, F. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100012s · Cited by 168
Discovering Natural Product Modulators to Overcome Multidrug Resistance in Cancer Chemotherapy
Wu, C.-P., Ohnuma, S., & V. Ambudkar, S. (2011) · Current Pharmaceutical Biotechnology · doi:10.2174/138920111795163887 · Cited by 171
“However, only three major ABC drug transporters, including P-glycoprotein (Pgp; ABCB1), multidrug resistance protein 1 (MRP1; ABCC1) and ABCG2 (BCRP; MXR), are believed to seriously affect cancer chemotherapy [2, 4].”
BackgroundLi, W.-Q., Wang, Z., Hao, S., He, H., Wan, Y., Zhu, C., Sun, L.-P., Cheng, G., & Zheng, S.-Y. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b01540 · Cited by 172
Zeng, L., Pan, Y., Tian, Y., Wang, X., Ren, W., Wang, S., Lu, G., & Wu, A. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.04.006 · Cited by 171
“The multidrug resistance (MDR) of chemotherapy drugs was leading to the failures of chemotherapy in about 90% cancer patients, which restricted the development of chemotherapy [1].”
BackgroundMicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN
Wang, F., Li, T., Zhang, B., Li, H., Wu, Q., Yang, L., Nie, Y., Wu, K., Shi, Y., & Fan, D. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.04.010 · Cited by 170
Multifunctional nanoplatforms for subcellular delivery of drugs in cancer therapy
Guo, X., Wei, X., Chen, Z., Zhang, X., Yang, G., & Zhou, S. (2020) · Progress in Materials Science · doi:10.1016/j.pmatsci.2019.100599 · Cited by 171
Madhusudhan, A., Reddy, G., Venkatesham, M., Veerabhadram, G., Kumar, D., Natarajan, S., Yang, M.-Y., Hu, A., & Singh, S. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15058216 · Cited by 170
“Although great efforts have been made to overcome MDR, only limited success has been achieved in clinical use [4].”
BackgroundMarcoux, J., Wang, S. C., Politis, A., Reading, E., Ma, J., Biggin, P. C., Zhou, M., Tao, H., Zhang, Q., Chang, G., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303888110 · Cited by 170
“P (P-gp) is an ATP-driven low-specificity efflux pump that plays an important role in the clearance of xenotoxins (1, 2).”
BackgroundWu, X., Zhao, J., Ruan, Y., Sun, L., Xu, C., & Jiang, H. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-1101-0 · Cited by 170
Role of cellular uptake in the reversal of multidrug resistance by PEG-b-PLA polymeric micelles
Xiao, L., Xiong, X., Sun, X., Zhu, Y., Yang, H., Chen, H., Gan, L., Xu, H., & Yang, X. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.03.071 · Cited by 169
“A large number of Pgp inhibitors have been developed, however clinical trials using these inhibitors have shown limited success, largely due to the lack of specificity and efficacy [8].”
BackgroundTyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance
Shukla, S., Chen, Z.-S., & Ambudkar, S. V. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.01.005 · Cited by 168
“Multidrug resistance Multidrug resistance (MDR) is a phenomenon that occurs when cancer cells develop resistance to a variety of anticancer drugs that are structurally and mechanistically unrelated (Szakacs et al., 2006).”
BackgroundPro-survival autophagy and cancer cell resistance to therapy
Das, C. K., Mandal, M., & Kögel, D. (2018) · Cancer and Metastasis Reviews · doi:10.1007/s10555-018-9727-z · Cited by 167
Role of ABC transporters in cancer chemotherapy
Sun, Y.-L., Patel, A., Kumar, P., & Chen, Z.-S. (2012) · Chinese Journal of Cancer · doi:10.5732/cjc.011.10466 · Cited by 166
Hall, M. D., Salam, N. K., Hellawell, J. L., Fales, H. M., Kensler, C. B., Ludwig, J. A., Szakács, G., Hibbs, D. E., & Gottesman, M. M. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm800861c · Cited by 167
Self-citationZhao, X., Chen, Q., Li, Y., Tang, H., Liu, W., & Yang, X. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.003 · Cited by 166
Imaging the Function of P-Glycoprotein With Radiotracers: Pharmacokinetics and In Vivo Applications
Kannan, P., John, C., Zoghbi, S. S., Halldin, C., Gottesman, M. M., Innis, R. B., & Hall, M. D. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.138 · Cited by 166
Self-citationMimeault, M., Hauke, R., & Batra, S. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100296 · Cited by 168
Paclitaxel And Docetaxel Resistance: Molecular Mechanisms and Development of New Generation Taxanes
Galletti, E., Magnani, M., Renzulli, M. L., & Botta, M. (2007) · ChemMedChem · doi:10.1002/cmdc.200600308 · Cited by 164
Wang, H., Wang, Z., Zhang, Z., Liu, J., & Li, H. (2023) · Advances in Nutrition · doi:10.1016/j.advnut.2023.05.013 · Cited by 183
Li, G. (2010) · International Journal of Oncology · doi:10.3892/ijo_00000659 · Cited by 168
Saraswathy, M., & Gong, S. (2014) · Materials Today · doi:10.1016/j.mattod.2014.05.002 · Cited by 163
Microparticles and their emerging role in cancer multidrug resistance
Gong, J., Jaiswal, R., Mathys, J.-M., Combes, V., Grau, G. E. R., & Bebawy, M. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.06.005 · Cited by 165
Chen, K. G., Valencia, J. C., Gillet, J., Hearing, V. J., & Gottesman, M. M. (2009) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2009.00630.x · Cited by 162
“The substrates of the transporters range from small ions, sugars, and peptides to more complex organic molecules (Dean and Annilo, 2005; Deeley et al., 2006; Doyle and Ross, 2003; Gottesman and Ling, 2006; Gottesman et al., 2002; Robey et al., 2007; Szakacs et al., 2006).”
BackgroundSelf-citationSusa, M., Iyer, A. K., Ryu, K., Hornicek, F. J., Mankin, H., Amiji, M. M., & Duan, Z. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-399 · Cited by 164
“Unfortunately, these compounds are often nonspecific and have low efficiency and/ or high toxicity; as such, phase 3 clinical trials of these agents are largely disappointing [7,8,11-14].”
BackgroundCancer stem cells and cancer therapy
Soltanian, S., & Matin, M. M. (2011) · Tumor Biology · doi:10.1007/s13277-011-0155-8 · Cited by 159
“These include biricodar and GF-120918, which inhibit not only P-glycoprotein but also MRP1 and ABCG2, respectively [53, 147].”
BackgroundMarquardt, J. U., Fischer, K., Baus, K., Kashyap, A., Ma, S., Krupp, M., Linke, M., Teufel, A., Zechner, U., Strand, D., et al. (2013) · Hepatology · doi:10.1002/hep.26413 · Cited by 164
An overview of the effective combination therapies for the treatment of breast cancer
Núñez, C., Capelo, J. L., Igrejas, G., Alfonso, A., Botana, L. M., & Lodeiro, C. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.04.027 · Cited by 162
Khan, A. Q., Rashid, K., AlAmodi, A. A., Agha, M. V., Akhtar, S., Hakeem, I., Raza, S. S., & Shahab Uddin, M. S. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112142 · Cited by 174
Yang, X., lyer, A. K., Singh, A., Choy, E., Hornicek, F. J., Amiji, M. M., & Duan, Z. (2015) · Scientific Reports · doi:10.1038/srep08509 · Cited by 158
Nrf2 Pathway Regulates Multidrug-Resistance-Associated Protein 1 in Small Cell Lung Cancer
Ji, L., Li, H., Gao, P., Shang, G., Zhang, D. D., Zhang, N., & Jiang, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063404 · Cited by 158
“Taken together, theses data suggested that Nrf2-ARE pathway is required for the regulatory expression of Mrp1 and implicated Nrf2 as a new therapeutic target for MDR. Citation: Ji L, Li H, Gao P, Shang G, Zhang DD, et al. (2013) Nrf2 Pathway Regulates Multidrug-Resistance-Associated Protein 1 in Small Cell Lung Cancer.”
InfluentialContinuous Quinacrine Treatment Results in the Formation of Drug-Resistant Prions
Ghaemmaghami, S., Ahn, M., Lessard, P., Giles, K., Legname, G., DeArmond, S. J., & Prusiner, S. B. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000673 · Cited by 158
“Because the efflux of quinacrine from the brain is governed by Pgp, an mdr-associated protein [14,16], active transport can be inhibited by the deletion of the mdr1a and mdr1b genes (MDR) or the co-administration of Pgp inhibitors [18].”
BackgroundCopsel, S., Garcia, C., Diez, F., Vermeulem, M., Baldi, A., Bianciotti, L. G., Russel, F. G. M., Shayo, C., & Davio, C. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.166868 · Cited by 158
Batrakova, E. V., Li, S., Brynskikh, A. M., Sharma, A. K., Li, Y., Boska, M., Gong, N., Mosley, R. L., Alakhov, V. Y., & Gendelman, H. E. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.01.004 · Cited by 157
“Appearance of MDR is a serious problem [1–5] that at least in some cases is believed to impede outcomes of chemotherapeutic regimens in treatment of cancer [6].”
BackgroundSusa, M., Iyer, A. K., Ryu, K., Choy, E., Hornicek, F. J., Mankin, H., Milane, L., Amiji, M. M., & Duan, Z. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010764 · Cited by 157
“have low efficiency and/or high toxicity; as such, phase 3 clinical trials of these agents are largely disappointing [6,7,10,11,12,13].”
BackgroundGenovese, I., Ilari, A., Assaraf, Y. G., Fazi, F., & Colotti, G. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.10.003 · Cited by 156
“Enhanced efflux of chemotherapeutic drugs by at least 15 ABC exporters has been shown to mediate MDR in cancer cells (Fletcher et al., 2016; Li et al., 2016b; Szakacs et al., 2006).”
BackgroundLung cancer stem cells: The root of resistance
MacDonagh, L., Gray, S. G., Breen, E. P., Cuffe, S. D., Finn, S. P., O'Byrne, K. J., & Barr, M. P. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.01.012 · Cited by 170
“Despite intense efforts to overcome such resistance in lung cancer and other cancer types using novel agents, alone and in combination with chemo- and radiotherapy, the underlying mechanisms conferring this resistant phenotype in lung cancer remain largely unknown [6].”
BackgroundChen, Y., Chen, H., & Shi, J. (2014) · Molecular Pharmaceutics · doi:10.1021/mp400596v · Cited by 158
Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters
Okabe, M., Szakács, G., Reimers, M. A., Suzuki, T., Hall, M. D., Abe, T., Weinstein, J. N., & Gottesman, M. M. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0539 · Cited by 173
“In addition to P-glycoprotein, 11 of 48 known human ABC transporters have been shown to play some role in the drug resistance of cancer cells in vivo and/or in vitro (4).”
BackgroundSelf-citationPoly(Ethylene Glycol)–Polylactide Micelles for Cancer Therapy
Wang, J., Li, S., Han, Y., Guan, J., Chung, S., Wang, C., & Li, D. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00202 · Cited by 155
“Active targeting is another effective method to reduce the damage of chemotherapeutic drugs to normal tissues (Allen, 2002; Szakács et al., 2006).”
MethodBao, L., Haque, A., Jackson, K., Hazari, S., Moroz, K., Jetly, R., & Dash, S. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.10.029 · Cited by 159
“The overexpression of ATP-binding cassette (ABC) transporters, including P-glycoprotein, multidrug resistance-associated protein 1 (MDR1), and BCRP, is one of the most common causes of multidrug resistance.(31,39) Other drug-resistant mechanisms have been proposed, including misregulation of drug-induced DNA repair pa…”
BackgroundFan, L., Li, F., Zhang, H., Wang, Y., Cheng, C., Li, X., Gu, C., Yang, Q., Wu, H., & Zhang, S. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.03.066 · Cited by 161
“Existing chemotherapeutic drugs are far from perfect with limitations such as lack of tumor selectivity, and intrinsic or acquired drug resistance [1,2].”
BackgroundRole of pancreatic stellate cells in chemoresistance in pancreatic cancer
McCarroll, J. A., Naim, S., Sharbeen, G., Russia, N., Lee, J., Kavallaris, M., Goldstein, D., & Phillips, P. A. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00141 · Cited by 175
“…factor α; TRAIL, TNF-related apoptosis-inducing ligand. uptake; (2) increased energy-dependent drug efflux; and (3) alterations in cellular capabilities affecting drug cytotoxicity, such as reduced apoptosis and dysregulated drug metabolism (Szakacs et al., 2006; Zalatnai and Molnar, 2007).”
BackgroundChoi, D., Choi, D., Hong, B. S., Jang, S. C., Kim, D., Lee, J., Kim, Y., Kim, K. P., & Gho, Y. S. (2012) · Journal of Extracellular Vesicles · doi:10.3402/jev.v1i0.18704 · Cited by 172
“Chemotherapeutics are the most effective treatment for metastatic cancer but cancer cells can acquire simultaneous resistance to different drugs, a phenomenon known as multidrug resistance (63).”
BackgroundPeng, X., Gong, F., Chen, Y., Jiang, Y., Liu, J., Yu, M., Zhang, S., Wang, M., Xiao, G., & Liao, H. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.297 · Cited by 154
Metadata
- Authors
- Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M.
- Affiliations
- Institute of Molecular Life Sciences (HU)
- National Institutes of Health (US)
- Corresponding author
- Gottesman, Michael M.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-03
- Volume
- 5
- Issue
- 3
- Pages
- 219-234
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2055904567
- Cited by
- 3,609
- References
- 265
- Citations by year
- 2026: 62 · 2025: 119 · 2024: 149 · 2023: 196 · 2022: 172 · 2021: 210 · 2020: 226 · 2019: 194 · 2018: 234 · 2017: 228 · 2016: 246 · 2015: 247 · 2014: 232 · 2013: 230 · 2012: 199
- FWCI
- 11.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- multidrug resistance, ABC transporters, drug efflux, chemoresistance, ABC transporter inhibitors, cancer chemotherapy
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplasms, Drug Resistance, Multiple, ATP-Binding Cassette Transporters, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.